Candida susceptibility to fluconazole (F) and voriconazole (V) at a single cancer center.

Mujica M 1, Garcia-Damiano M 2, Dignani M 2, Tula L 2, Jewtuchowicz V 1, Scarano S 1, Iovannitti C 1, Finquelevich J 1

Author address: 

1 Centro de Micologia, Dep. Microbiologí­a, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina, 2 FUNDALEU (Fundación de lucha contra la Leucemia), Buenos Aires, Argentina.

Abstract: 

Introduction: Fungal infections are a major cause of morbidity among cancer patients. The availability and widespread use of antifungal agents belonging to the azoles family may change the patterns of yeasts susceptibility to certain drugs. Objective: To evaluate the susceptibility to F and V of clinical isolates of Candida species obtained from patients taken care at a single referral cancer center where azoles agents have been used since 1994 for treatment or prophylaxis. Methods: From 5/03 to 12/04, 110 Candida spp. considered being colonizers (107) or pathogenic (3) were studied for susceptibility to F and V using the disk diffusion testing for yeasts (NCCLS M44-P). Yeast identification was done using the CHROMagar® (CHROMagar Co. Paris, France), and the API ID32C® (Biomerieux, France). Clinical data on age, underlying disease, neutropenia, reason for culture, and prior use of antifungal agents, was obtained by chart review. Results: 110 strains (C. albicans 75, C. tropicalis 15, C. glabrata 10, C. krusei 6, C. parapsilosis 3, Candida spp. 1) were isolated from 102 samples obtained from 68 patients with leukemia (24), multiple myeloma (18), lymphoma (17), solid tumors (2) and other (7). 22 of 68 patients were neutropenic (
2005

abstract No: 

9

Full conference title: 

15th Annual Focus on Fungal Infections
    • FFI 15th (2005)